Spine PRISM MarketView Showcases Aclarion: Disrupting Chronic Pain Treatment with Nociscan AI Technology byJosh SandbergSeptember 13, 2024
Spine Top Stories Aclarion Provides Corporate Update on Nociscan AI Technology Milestones byJosh SandbergSeptember 12, 2024
Spine Aclarion Announces Completion of First Nociscan Exams in LIFEHAB Trial byJosh SandbergSeptember 10, 2024
Financial Spine Top Stories Aclarion Added to PRISM Emerging Medical Devices Index byJosh SandbergSeptember 6, 2024
Spine Aclarion Launches Second Clinical Utility and Economic (CLUE) Trial Site With First Surgeon in New Jersey byTim AllenAugust 29, 2024
Spine Aclarion Launches the Clinical Utility and Economic (CLUE) Trial to Quantify How Often Nociscan’s AI Generated Biomarker Data Changes Surgical Treatment Plans byJosh SandbergAugust 21, 2024
Hospitals Spine Top Stories Aclarion Announces First Commercial Agreement in Michigan byJosh SandbergAugust 14, 2024
Financial Hospitals Aclarion Hits Another Key Milestone by Adding Vitality – Third Major Payer to Cover Nociscan in Greater UK byJosh SandbergAugust 13, 2024
Financial Aclarion Achieves Milestone With Key Second Payer Coverage of Nociscan by Aviva Throughout Greater London, UK byTim AllenJuly 9, 2024
Spine Aclarion Expands Commercial Engagement With The London Clinic to Grow Access to Nociscan Throughout Greater London byJosh SandbergJune 25, 2024
